Kingella kingae is an emerging pathogen predominantly associated with pediatric infections. With our extensive experience and advanced capabilities, we are committed to providing specialized vaccine and therapeutic development solutions to support your efforts in combating Kingella kingae infections.
Introduction to Kingella Kingae Infection
Kingella kingae is an emerging Gram-negative bacterial pathogen that primarily affects young children, causing a range of serious infections. Initially considered a harmless commensal organism, Kingella kingae is now recognized as a significant threat, capable of causing life-threatening conditions such as septicemia, endocarditis, and devastating osteoarticular infections, including septic arthritis and osteomyelitis.
Fig.1 The outer membrane tbpA and hpuB proteins of Kingella kingae. (Mashraqi M. M., et al., 2023)
Vaccine Development for Kingella Kingae Infection
Chimeric Vaccines
At the forefront of vaccine development is the design of chimeric vaccines, which incorporate multiple antigenic epitopes to elicit a broad and potent immune response. The use of bioinformatics tools has accelerated the identification of B- and T-cell epitopes from conserved protein domains, such as the TonB-dependent receptor-like β-barrel domain found in outer membrane proteins of K. kingae.
Subunit Vaccines
Subunit vaccines, which include only specific parts of the pathogen, have been developed using epitopes derived from the tbpA and hpuB proteins of Kingella kingae. These epitopes are predicted to be highly immunogenic and conserved across strains, offering the potential for a vaccine with broad population coverage.
Therapeutics Development for Kingella Kingae Infection
The cornerstone of Kingella kingae infection therapeutic is antibiotic therapy. Most strains are susceptible to a range of antibiotics, including oral and parenteral options commonly prescribed for febrile children. However, the emergence of β-lactamase-producing strains has necessitated the development of strategies to monitor and manage resistance effectively.
In the context of outbreaks, prophylactic antibacterial drugs, such as rifampin, have been proposed to prevent further cases. Rifampin's activity against Kingella kingae, coupled with its secretion in saliva and high concentrations in the upper respiratory tract mucosa, makes it a candidate for eradicating the bacterium and related invasive pathogens.
Despite the potential of prophylactic therapeutics, the management of Kingella kingae outbreaks remains challenging. Our company provides one-stop solutions for the development of therapeutics for Kingella kingae infection. You can click on the link below to learn more.
Our Services
In our organization, we provide a full range of services to assist in the creation of potent vaccines and therapeutics for Kingella kingae infections. Our team of experts, proficient in cutting-edge microbiology, immunology, and drug discovery technologies, is committed to expediting the advancement of your Kingella kingae research and development endeavors.
Infectious Disease Models
- Genotype-Phenotype Correlation Models
- Septic Arthritis and Osteomyelitis Models
- Intraperitoneal Inoculation Models
- Endocarditis Models
- Age-Dependent Susceptibility Models
We provide preclinical research services that encompass in vitro and in vivo studies to evaluate the safety, immunogenicity, and efficacy of our vaccine and therapy candidates. Our services include molecular dynamics simulation to assess the stability and conformational dynamics of these candidates. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and to obtain a detailed quotation for the services you require.
Reference
- Mashraqi, Mutaib M., et al. "Chimeric vaccine design against the conserved TonB-dependent receptor-like β-barrel domain from the outer membrane tbpA and hpuB proteins of Kingella kingae ATCC 23330." Frontiers in Molecular Biosciences 10 (2023): 1258834.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
